

1. Use of papaverine-like vasodilator for the production of a pharmaceutical composition for the treatment of ophthalmological dysfunctions which are linked to circulatory disturbances of the eye or which are to be attributed to circulatory disturbances of the eye, wherein the pharmaceutical composition is to be applied topically to the eye.

2. Use as set forth in claim 1 characterised in that the papaverine-like vasodilator is selected from the group which consists of papaverine, ethaverine, moxaverine, elziverine, their pharmacologically compatible salts and mixtures thereof.

3. Use as set forth in one of the preceding claims characterised in that the ophthalmological dysfunctions are selected from the group which consists of glaucoma and ophthalmological dysfunctions linked to diabetes, for example neovascularisation glaucoma, hemorrhagic glaucoma or diabetic retinopathy.

4. Use as set forth in one of claims 1 through 3 characterised in that the pharmaceutical composition is in the form of eye drops, eye ointments, eye spray, eye tablet, gel, suspension, emulsion, powder or granules.

5. Use as set forth in one of the preceding claims characterised in that the pharmaceutical composition additionally includes a viscosity regulator.

6. Use as set forth in claim 5 characterised in that the viscosity regulator is selected from the group which consists of chondroitin sulfate, polyacrylamide, polyacrylic acid, polyacrylic resins, polyethylene glycol, cellulose derivatives, polyvinyl alcohol, polyvinyl pyrrolidone, hyaluronic acid, hyaluronates and mixtures thereof.

7. A pharmaceutical composition which includes papaverine-like vasodilator and pharmacologically compatible viscosity regulator, wherein the papaverine-like vasodilator is selected from the group which consists of ethaverine, moxaverine, elziverine, their pharmacologically compatible salts and mixtures thereof.

8. A pharmaceutical composition as set forth in claim 7 characterised in that the viscosity regulator is selected from the group which consists of chondroitin sulfate, polyacrylamide, polyacrylic acid, polyacrylic resins, polyethylene glycol, cellulose derivatives, polyvinyl alcohol, polyvinyl pyrrolidone, hyaluronic acid, hyaluronates and mixtures thereof.

9. A pharmaceutical composition as set forth in one of claims 7 and 8 characterised in that the pharmaceutical composition is in the form of eye drops, eye ointments, eye spray, eye tablet, gel, suspension, emulsion, powder or granules.